Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Announces Addition of Twirla® to a Preferred Drug Position on Medi-Cal Formulary
Largest Medicaid program in the U.S. adds Twirla to Preferred Drug List as of October 1, 2021 PRINCETON, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX ), a women's healthcare company, announced today that the California Medicaid Program, Medi-Cal, has placed Twirla...
Toggle Summary Agile Therapeutics Partners with Carli Lloyd, U.S. Women’s Soccer Star and Four-Time Olympian, to Bring Awareness to Women’s Health Topics
Partnership to focus on empowering women to take ownership of their health and healthcare options PRINCETON, N.J., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX ), a women's healthcare company, announced today a partnership with U.S. Women’s Soccer legend, Carli Lloyd ....
Toggle Summary Agile Therapeutics to Participate in Upcoming Investor Conferences
PRINCETON, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that management will present and participate at the following virtual investor conferences during the month of September 2021. H.C....
Toggle Summary Agile Therapeutics Partners with Telehealth Service, Pandia Health, to Increase Women’s Access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system
Pandia Health is a doctor founded and led telehealth company, offering online prescriptions and free delivery designed to make it easier for women to access birth control options that meet their needs Partnership represents first telehealth alliance for Agile’s Twirla ® birth control patch...
Toggle Summary Agile Therapeutics Reports Second Quarter 2021 Financial Results
Total Prescriptions (TRx) Grew 171% in Second Quarter Prescribers, New Prescriptions and Refill Rates Continue to Grow in Second Quarter Company Continues to Progress on Expanding Access to Twirla Management to Host Conference Call Today, Monday, July 26, 2021 at 4:30 p.m....
Toggle Summary Agile Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on Monday, July 26, 2021
Live Conference Call and Webcast at 4:30 p.m. EDT PRINCETON, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report second quarter 2021 financial results after the market close on Monday, July 26, 2021 as...
Toggle Summary Agile Therapeutics to Participate in the William Blair 41st Annual Growth Stock Conference
PRINCETON, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the company will be participating virtually in the William Blair 41 st Annual Growth Stock Conference. Chairman and Chief Executive Officer Al Altomari is...
Toggle Summary Agile Therapeutics to Participate in Virtual Fireside Chat as Part of the 2021 RBC Capital Markets Global Healthcare Conference
PRINCETON, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat as part of the 2021 RBC Capital Markets Global Healthcare...
Toggle Summary Agile Therapeutics Reports First Quarter 2021 Financial Results
Prescription Growth Reflects Increasing Demand for Twirla Base of Prescribers Continues to Grow in First Quarter 2021 Growing Distribution Network and Marketing Efforts Expected to Drive Healthcare Provider and Consumer Engagement PRINCETON, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Agile...
Toggle Summary Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women of Differing BMI Categories at ACOG Annual Meeting
PRINCETON, N.J. , April 30, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics , Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial evaluating the safety and efficacy of Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system...
Shadow